OncoMatch/Clinical Trials/NCT06688305

68Ga-NI-FAPI PET/CT: First-in-human Study

Is NCT06688305 recruiting? Yes, currently enrolling (May 2026). This Early Phase 1 trial studies 68Ga-NI-FAPI for malignant neoplasm.

Early Phase 1RecruitingFirst Affiliated Hospital of Fujian Medical UniversityNCT06688305Data as of May 2026

Treatment: 68Ga-NI-FAPI — 68Ga-NI-FAPI is a novel radiotracer incorporating a hypoxia sensitive nitroimidazole (NI)-moiety and a FAP-targeting. In this study, we observed the safety, biodistribution, radiation dosimetry and diagnostic value of 68Ga-NI-FAPI PET/CT in patients with different types of cancer.

Check if I qualify

Extracted eligibility criteria

Cancer type

Tumor Agnostic

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify